Can-Fite's Promising Psoriasis Drug Could Unseat Celgene's Latest Entrant
- Utilizing a novel biochemical pathway, Can-Fite's pipeline of drugs in mid-stage clinical trials targets large markets for disease where current drugs have drawbacks.
- Can-Fite's compound for psoriasis is showing similar efficacy to Celgene's Otezla, without the risky side effect drawbacks.
- Can-Fite is a micro-cap stock, and carries risks typically seen with small companies. Success in past psoriasis trials may not translate to future ones.